drugset
drugset / Trial / NCT04773964

Study to Evaluate MET642 in Patients With NASH

NCT04773964 ↗

Phase 2 Completed 215 enrolled Metacrine, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.

Timeline

Start
2021-03-03
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MET642 Unknown — —

Indications

metabolic dysfunction-associated steatohepatitis